JILL HUDNELL: Open Payments
NPI 1801331491 · LA PLATA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,268 in 67 payments from 16 companies in 2025. Trend: 2023 $23 · 2024 $137 · 2025 $1,268
Food & beverage: $1,268
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $381 |
| Esperion Therapeutics, Inc. | 6 | $146 |
| Corcept Therapeutics | 6 | $130 |
| Verona Pharma, Inc. | 5 | $103 |
| AstraZeneca Pharmaceuticals LP | 4 | $86 |
| Novo Nordisk Inc | 4 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| PFIZER INC. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $39 |
Products named: NEXLETOL, QULIPTA, Korlym, UBRELVY, VRAYLAR, Ohtuvayre, GEMTESA, AIRSUPRA.
Industry payments across MD — which companies pay providers there.
